Global Head of Development, Rare Diseases at Sanofi
Appears in 1 story
Leading rilzabrutinib development program
For 50,000 Americans with warm autoimmune hemolytic anemia, there's never been a disease-specific treatment. On February 9, 2026, the FDA granted breakthrough therapy designation to rilzabrutinib—the first BTK inhibitor to reach this milestone for the condition—signaling it may offer substantial improvement over existing therapies.
Updated May 27
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
